Brentuximab vedotin

From Self-sufficiency
Jump to: navigation, search
Brentuximab vedotin
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CD30
Identifiers
CAS Number 914088-09-8
ATC code none
Chemical data
Formula C6476H9930N1690O2030S40 (C68H105N11O15)3–5
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Brentuximab vedotin (SGN-35) is a drug being investigated for hematological malignancies like anaplastic large cell lymphoma[1] and Hodgkin's lymphoma.[2][3][4]

A molecule of the drug consists of the chimeric monoclonal antibody brentuximab and three to five units of the antimitotic agent monomethyl auristatin E (MMAE, reflected by the 'vedotin' in the drug's name). MMAE is responsible for the anti-tumour activity.[5][6]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. ClinicalTrials.gov NCT00866047 A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma
  2. ClinicalTrials.gov NCT00848926 A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma
  3. ClinicalTrials.gov NCT00649584 A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
  4. ClinicalTrials.gov NCT00430846 Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
  5. Seattle Genetics: Brentuximab vedotin (SGN-35)
  6. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.